RNA sequencing reveals the differential expression profiles of RNA in metastatic triple negative breast cancer and identifies SHISA3 as an efficient tumor suppressor gene.
SHISA3
Triple-negative breast cancer TNBC
biomarker
metastasis
prognosis
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
03
2021
accepted:
26
05
2021
entrez:
18
10
2021
pubmed:
19
10
2021
medline:
19
10
2021
Statut:
epublish
Résumé
Breast cancer metastasis is the second leading cause of female mortality worldwide. Because of the heterogeneity within the group, metastatic biomarkers for triple-negative breast cancer (TNBC) providing predictive and prognosis values are urgently needed. Using RNA-Seq, we analyzed the transcriptome profiles of two groups of TNBCs tumors with or without distant metastasis. Whole transcriptome sequencing identified a set of genes implicated in TNBC metastasis with major roles in cell-cell adhesion, immune-modulation, and Wnt/β-catenin pathways. We further selected the SHISA3 gene and studied its biological significance through a series of
Types de publication
Journal Article
Langues
eng
Pagination
4568-4581Informations de copyright
AJCR Copyright © 2021.
Déclaration de conflit d'intérêts
None.
Références
Crit Rev Oncol Hematol. 2020 Jan;145:102855
pubmed: 31927455
Cell. 2005 Jan 28;120(2):223-35
pubmed: 15680328
J Cancer. 2017 May 12;8(8):1453-1459
pubmed: 28638460
Int J Oncol. 2015 Sep;47(3):840-8
pubmed: 26202679
Cancers (Basel). 2019 Apr 18;11(4):
pubmed: 31003528
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1481-9
pubmed: 25968618
Am J Pathol. 2010 Jun;176(6):2911-20
pubmed: 20395444
Dev Biol. 2007 Jun 15;306(2):480-92
pubmed: 17481602
Dev Dyn. 2006 Sep;235(9):2567-73
pubmed: 16773659
Oncogene. 2017 Mar;36(11):1461-1473
pubmed: 27617575
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Oncogenesis. 2017 Apr 3;6(4):e310
pubmed: 28368389
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
F1000Res. 2018 Sep 18;7:
pubmed: 30271576
BMC Cancer. 2013 Nov 10;13:537
pubmed: 24209998
Front Oncol. 2018 Feb 22;8:31
pubmed: 29520340
PLoS One. 2015 Feb 06;10(2):e0117097
pubmed: 25658419
Trends Cell Biol. 2019 Mar;29(3):212-226
pubmed: 30594349
Anticancer Res. 2019 Oct;39(10):5285-5296
pubmed: 31570423
Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16654-9
pubmed: 23011797
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Drug Deliv Transl Res. 2018 Oct;8(5):1483-1507
pubmed: 29978332
Mod Pathol. 2011 Feb;24(2):209-31
pubmed: 21076461
Cancer Res. 2019 Feb 15;79(4):747-759
pubmed: 30573520
Nature. 2017 Jul 5;547(7661):E1-E3
pubmed: 28682326
PLoS One. 2020 Jul 21;15(7):e0236192
pubmed: 32692756
Cancer Sci. 2018 Nov;109(11):3368-3375
pubmed: 30137666
Am J Respir Crit Care Med. 2014 Aug 15;190(4):433-44
pubmed: 25036006
Mol Cancer. 2017 Jul 17;16(1):124
pubmed: 28716029
J Clin Med. 2016 Mar 28;5(4):
pubmed: 27043642
J Clin Med. 2019 Oct 11;8(10):
pubmed: 31614568
Biomed Res Int. 2017;2017:9058749
pubmed: 28299336
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099